Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

SANOFI : EMA Recommends Approval Of Sanofi Pediatric Vaccine Hexyon/Hexacima 6-in-1

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/22/2013 | 01:58pm CEST

PARIS--The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) recommended market approval for Sanofi Pasteur's 6-in-1 pediatric vaccine, French drugs giant Sanofi (>> SANOFI) said Friday.

MAIN FACTS:

- Hexyon/Hexacima is the only fully liquid, ready-to-use, 6-in-1 vaccine to protect infants against diphtheria, tetanus, pertussis (whooping cough), Hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b.

- The new vaccine will be commercialized under the brand name Hexyon in Western European countries by Sanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur, and under the brand name Hexacima in Eastern European countries by Sanofi Pasteur.

- The vaccine "reduces the number of vaccination visits for infants and it is more convenient for parents to complete the recommended vaccination schedule and thus better protect their children against six major childhood diseases," said Olivier Charmeil, President and CEO of Sanofi Pasteur.

-Hexyon/Hexacima would be indicated for primary and booster vaccination of infants from six weeks of age in accordance with official recommendations.

- The CHMP positive opinion is supported by results of multi-center clinical studies involving approximately 5,000 infants; phase III clinical studies comparing Hexyon/Hexacima to licensed combination vaccines demonstrated that HexyonTM/HexacimaTM is safe and induces a robust immune response against all six targeted diseases.

-Write to Mimosa Spencer at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
05/25 SANOFI : Data on Influenza Described by Researchers at Sanofi (Passive enhanced ..
05/25 ALNYLAM PHARMACEUTICALS, INC. (NASDA : ALNY) Files An 8-K Entry into a Material ..
05/25 SANOFI : FDA approves Sanofi and Regenerons Kevzara for adult rheumatoid arthrit..
05/24 SANOFI : Regeneron RA Drug Kevzara Wins FDA Approval
05/23 SANOFI : and Regeneron Announce FDA Approval of Kevzara (Sarilumab) for the Trea..
05/23 THE BUSINESS RESEARCH COMPANY : Asia accounted for $307 billion in the pharmaceu..
05/23 SANOFI : s insulin lispro receives CHMP positive opinion to treat diabetes
05/23 SANOFI : Phony Veterinary Labels Land Michael Chihwen Wang in the Doghouse
05/22 SANOFI : and Regeneron Announce FDA Approval of Kevzara® (sarilumab) for the Tre..
05/22 SANOFI SA : Blog Coverage: CHMP Okays French Pharma Major Sanofi's Insulin Lispr..
More news
Sector news : Pharmaceuticals - NEC
05/29 WARREN BUFFETT : Warren Buffett takes 3 percent stake in Germany's Lanxess
05/29DJMERCK : Congo Approves Anti-Ebola Vaccine to Combat Outbreak in Remote Northeast
05/26DJSUN PHARMACEUTICAL INDUSTRIES : Pharma 4Q Profit Falls 13.6%
05/24 JOHNSON & JOHNSON : J&J settles drug manufacturing probe by U.S. states for $33 ..
05/24 FTSE edges up helped by M&S, but miners weigh
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
05/29 VALEANT : Heading To Single Digits Again?
05/25 FDA drug approvals rebound from last year, up over 100% yoy
05/25 FDA chief says agency needs to play a role in constraining drug prices by eas..
05/24 Exelixis Could Still Be A Buy
05/24 3 THINGS IN BIOTECH YOU SHOULD LEARN : May 24, 2017 - FDA Makes History
Advertisement
Financials (€)
Sales 2017 36 691 M
EBIT 2017 9 442 M
Net income 2017 7 526 M
Debt 2017 3 541 M
Yield 2017 3,43%
P/E ratio 2017 14,81
P/E ratio 2018 18,16
EV / Sales 2017 3,11x
EV / Sales 2018 2,98x
Capitalization 110 387 M
More Financials
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 85,6 €
Spread / Average Target -2,3%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI13.94%122 703
JOHNSON & JOHNSON10.16%341 901
ROCHE HOLDING LTD.14.62%235 172
NOVARTIS AG6.07%210 841
PFIZER INC.-1.05%191 398
MERCK & CO., INC.10.28%177 567
More Results